Medical Policy
Allogeneic Pancreas Transplant

Table of Contents
• Policy: Commercial
• Policy: Medicare
• Authorization Information
• Coding Information
• Description
• Policy History
• Information Pertaining to All Policies
• References

Policy Number: 328
BCBSA Reference Number: 7.03.02
NCD/LCD: National Coverage Determination (NCD) for Pancreas Transplants (260.3)

Related Policies
• Kidney Transplant, #196
• Islet Transplantation, #324

Policy
Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

A combined pancreas-kidney transplant may be MEDICALLY NECESSARY in insulin dependent diabetic patients with uremia.

Pancreas transplant after a prior kidney transplant may be MEDICALLY NECESSARY in patients with insulin dependent diabetes.

Pancreas transplant alone may be MEDICALLY NECESSARY in patients with severely disabling and potentially life-threatening complications due to hypoglycemia unawareness and labile insulin-dependent diabetes that persists in spite of optimal medical management.

Pancreas retransplant after a failed primary pancreas transplant may be MEDICALLY NECESSARY in patients who meet criteria for pancreas transplantation.

In addition to the above information, we do not cover pancreas transplantation when any of the following conditions are present:
• Known current malignancy, including metastatic cancer
• Recent malignancy with high risk of recurrence
Note: the assessment of risk of recurrence for a previously treated malignancy is made by the transplant team; providers must submit a statement with an explanation of why the patient with a recently treated malignancy is an appropriate candidate for a transplant.

- Untreated systemic infection making immunosuppression unsafe, including chronic infection
- Other irreversible end-stage disease not attributed to kidney disease
- History of cancer with a moderate risk of recurrence
- Systemic disease that could be exacerbated by immunosuppression
- Psychosocial conditions or chemical dependency affecting ability to adhere to therapy.

Candidates for pancreas transplant alone should additionally meet 1 of the following severity of illness criteria:

- Documentation of severe hypoglycemia unawareness as evidenced by chart notes or emergency department visits; OR
- Documentation of potentially life-threatening labile diabetes, as evidenced by chart notes or hospitalization for diabetic ketoacidosis.

In addition, most pancreas transplant patients will have type 1 diabetes mellitus. Those transplant candidates with type 2 diabetes mellitus, in addition to being insulin-dependent, should also not be obese (body mass index [BMI] should be 32 or less).

Pancreas transplant is considered INVESTIGATIONAL in all other situations.

**Medicare HMO BlueSM and Medicare PPO BlueSM Members**

Medical necessity criteria and coding guidance can be found through the link below.

[National Coverage Determination (NCD) for Pancreas Transplants (260.3)]

**Nationally Non-Covered Indications**

Transplantation of partial pancreatic tissue or islet cells (except in the context of a clinical trial (see section 260.3.1 of the National Coverage Determinations Manual).

**Prior Authorization Information**

Pre-service approval is required for all inpatient services for all products. See below for situations where prior authorization may be required or may not be required for outpatient services.

Yes indicates that prior authorization is required.
No indicates that prior authorization is not required.
N/A indicated that this service is primarily performed in an inpatient setting.

<table>
<thead>
<tr>
<th>Outpatient</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Commercial Managed Care (HMO and POS)</td>
<td>N/A</td>
</tr>
<tr>
<td>Commercial PPO and Indemnity</td>
<td>N/A</td>
</tr>
<tr>
<td>Medicare HMO BlueSM</td>
<td>N/A</td>
</tr>
<tr>
<td>Medicare PPO BlueSM</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**CPT Codes / HCPCS Codes / ICD Codes**

*Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.*
Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The above medical necessity criteria MUST be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity:

### CPT Codes

<table>
<thead>
<tr>
<th>CPT codes</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>48554</td>
<td>Transplantation of pancreatic allograft</td>
</tr>
</tbody>
</table>

### HCPCS Codes

<table>
<thead>
<tr>
<th>HCPCS codes</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>S2065</td>
<td>Simultaneous pancreas kidney transplantation</td>
</tr>
</tbody>
</table>

### ICD-10 Procedure Codes

<table>
<thead>
<tr>
<th>ICD-10-PCS procedure codes</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0FYG0Z0</td>
<td>Transplantation of Pancreas, Allogeneic, Open Approach</td>
</tr>
<tr>
<td>0FSG0ZZ</td>
<td>Reposition Pancreas, Open Approach</td>
</tr>
<tr>
<td>0FSG4ZZ</td>
<td>Reposition Pancreas, Percutaneous Endoscopic Approach</td>
</tr>
</tbody>
</table>

### Description

**DIABETES AND PANCREATITIS**

Insulin independence with resultant decreased morbidity and increased quality of life is the primary health outcome of pancreas transplantation. While pancreas transplantation is generally not considered a life-saving treatment, in a small subset of patients who experience life-threatening complications from diabetes, pancreas transplantation could be considered life-saving. Pancreas transplant alone (PTA) has also been investigated in patients following total pancreatectomy for chronic pancreatitis. In addition to the immune rejection issues common to all allograft transplants, autoimmune destruction of beta cells has been observed in the transplanted pancreas, presumably from the same mechanism responsible for type 1 diabetes.

### Treatment

Pancreas transplantation occurs in several different scenarios such as (1) a diabetic patient with renal failure who may receive a simultaneous cadaveric pancreas plus kidney transplants; (2) a diabetic patient who may receive a cadaveric or living-related pancreas transplant after a kidney transplantation (pancreas after kidney); or (3) a nonuremic diabetic patient with specific severely disabling and potentially life-threatening diabetic problems who may receive a PTA. The total number of adult pancreas transplants (pancreas and pancreas plus kidney) in the United States peaked at 1484 in 2004 and has since steadily declined. In 2017, 213 PTAs and 789 simultaneous pancreas plus kidneys were performed in the United States.

Most patients undergoing PTA are those with either hypoglycemic unawareness or labile diabetes. However, other exceptional circumstances may exist where nonuremic type 1 diabetes patients have significant morbidity risks due to secondary complications of diabetes (eg, peripheral neuropathy) that exceed those of the transplant surgery and subsequent chronic immunosuppression. Because virtually no published evidence addresses outcomes of medical management in this very small group of exceptional diabetic patients, it is not possible to generalize about which circumstances represent appropriate
indications for PTA. Case-by-case consideration of each patient’s clinical situation may be the best option for determining the balance of risks and benefits.

According to the International Pancreas Transplant Registry data, the proportion of pancreas transplant recipients worldwide who have type 2 diabetes has increased over time, from 2% in 1995 to 7% in 2010. In 2010, approximately 8% of simultaneous pancreas plus kidney transplants, 5% of pancreas transplant after kidney transplant, and 1% of PTA were performed in patients with type 2 diabetes.

The approach to retransplantation varies by cause of failure. Surgical and technical complications such as venous thrombosis are the leading cause of pancreatic graft loss among diabetic patients. Graft loss from chronic rejection may result in sensitization, increasing both the difficulty of finding a cross-matched donor and the risk of rejection of a subsequent transplant. Each transplant center has guidelines based on experience; some centers may wait to allow reconstitution of the immune system before initiating retransplant with an augmented immunosuppression protocol.

**Summary**

For individuals who have insulin-dependent diabetes who receive a pancreas transplant after a kidney transplant, the evidence includes case series and registry studies. Relevant outcomes are overall survival, change in disease status, and treatment-related mortality and morbidity. Data from national and international registries have found relatively high patient survival rates with a pancreas transplant after a kidney transplant (eg, a 3-year survival rate of 93%). A 2012 analysis of data from a single center found similar patient survival and death-censored pancreas graft survival rates with a pancreas transplant after a kidney transplant or an SPK transplant. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have insulin-dependent diabetes with uremia who receive SPK transplants, the evidence includes registry studies. Relevant outcomes are overall survival, change in disease status, and treatment-related mortality and morbidity. Data from national and international registries have found relatively high patient survival rates after SPK transplant. A retrospective analysis found a higher survival rate in patients with type 1 diabetes who had an SPK transplant vs those on a waiting list. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have insulin-dependent diabetes and severe complications who receive pancreas transplant alone, the evidence includes registry studies. Relevant outcomes are overall survival, change in disease status, and treatment-related mortality and morbidity. Data from international and national registries have found that graft and patient survival rates after pancreas transplant alone have improved over time (eg, 3-year survival of 95%). The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have had a prior pancreas transplant who still meet criteria for a pancreas transplant who receive pancreas retransplantation, the evidence includes case series and registry studies. Relevant outcomes are overall survival, change in disease status, and treatment-related mortality and morbidity. National data and specific transplant center data have generally found similar graft and patient survival rates after pancreas retransplantation compared with initial transplantation. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

**Policy History**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>9/2017</td>
<td>New references added from BCBSA National medical policy.</td>
</tr>
<tr>
<td>5/2015</td>
<td>Clarified coding language.</td>
</tr>
<tr>
<td>4/2015</td>
<td>BCBSA National medical policy review.</td>
</tr>
<tr>
<td>Date</td>
<td>Description</td>
</tr>
<tr>
<td>----------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>6/2014</td>
<td>Updated Coding section with ICD10 procedure and diagnosis codes, effective 10/2015.</td>
</tr>
<tr>
<td>11/2011-</td>
<td>Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.</td>
</tr>
<tr>
<td>4/2012</td>
<td></td>
</tr>
<tr>
<td>4/2008</td>
<td>BCBSA National medical policy review. No changes to policy statements.</td>
</tr>
</tbody>
</table>

**Information Pertaining to All Blue Cross Blue Shield Medical Policies**

Click on any of the following terms to access the relevant information:

- **Medical Policy Terms of Use**
- **Managed Care Guidelines**
- **Indemnity/PPO Guidelines**
- **Clinical Exception Process**
- **Medical Technology Assessment Guidelines**

**References**


